These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29378714)

  • 1. Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery.
    Grégoire M; Libois JB; Waast D; Gaborit B; Dauty M; Deslandes G; Dailly E; Touchais S; Boutoille D; Grégoire N; Couet W
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tedizolid population pharmacokinetics, exposure response, and target attainment.
    Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults.
    Pai MP
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4585-9. PubMed ID: 27185808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects.
    Flanagan S; Minassian SL; Passarell JA; Fiedler-Kelly J; Prokocimer P
    J Clin Pharmacol; 2017 Oct; 57(10):1290-1294. PubMed ID: 28510339
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.
    Keel RA; Tessier PR; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4403-7. PubMed ID: 22687504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tedizolid (TR-701): a new oxazolidinone with enhanced potency.
    Kanafani ZA; Corey GR
    Expert Opin Investig Drugs; 2012 Apr; 21(4):515-22. PubMed ID: 22324973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
    Srivastava S; Deshpande D; Nuermberger E; Lee PS; Cirrincione K; Dheda K; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S336-S341. PubMed ID: 30496463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative
    Wang S; Li Y; Xue F; Liu J; Yang W; Zhang J; Glenschek-Sieberth M; Lyu Y
    J Chemother; 2019 Oct; 31(6):313-319. PubMed ID: 31215343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
    Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.
    Flanagan S; McKee EE; Das D; Tulkens PM; Hosako H; Fiedler-Kelly J; Passarell J; Radovsky A; Prokocimer P
    Antimicrob Agents Chemother; 2015 Jan; 59(1):178-85. PubMed ID: 25331703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.
    Ferrández O; Urbina O; Grau S
    Drug Des Devel Ther; 2017; 11():65-82. PubMed ID: 28053508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.
    Housman ST; Pope JS; Russomanno J; Salerno E; Shore E; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 May; 56(5):2627-34. PubMed ID: 22330925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers.
    Sahre M; Sabarinath S; Grant M; Seubert C; Deanda C; Prokocimer P; Derendorf H
    Int J Antimicrob Agents; 2012 Jul; 40(1):51-4. PubMed ID: 22584101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.
    Deshpande D; Srivastava S; Nuermberger E; Koeuth T; Martin KR; Cirrincione KN; Lee PS; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S342-S348. PubMed ID: 30496456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.
    Werth BJ
    J Antimicrob Chemother; 2017 May; 72(5):1410-1414. PubMed ID: 28158617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.
    Rodríguez-Avial I; Culebras E; Betriu C; Morales G; Pena I; Picazo JJ
    J Antimicrob Chemother; 2012 Jan; 67(1):167-9. PubMed ID: 21954458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections.
    Delpech P; ALeryan M; Jones B; Gemmell C; Lang S
    Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative activity of tedizolid against clinical isolates of linezolid-resistant coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus.
    Pérez-Parra S; Peña-Monje A; Recio JL; García-García F
    Enferm Infecc Microbiol Clin; 2017 May; 35(5):323-324. PubMed ID: 27743684
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of Tedizolid against Enterococci and Staphylococci, Including
    Singh KV; Arias CA; Murray BE
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.